Clicky

Lyra Therapeutics, Inc.(LYRA)

Description: Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions using XTreo technology platform for the localized treatment of patients with ear, nose, and throat diseases. Its XTreo platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210 and LYR-220, which are bioresorbable polymeric matrices for the treatment of chronic rhinosinusitis. Lyra Therapeutics, Inc. was founded in 2005 and is headquartered in Watertown, Massachusetts.


Keywords: Headache Sinus Sinusitis Chronic Rhinosinusitis

Home Page: lyratherapeutics.com

LYRA Technical Analysis

480 Arsenal Way
Watertown, MA 02472
United States
Phone: 617 393 4600


Officers

Name Title
Dr. Maria Palasis Ph.D. CEO, Pres & Director
Mr. Jason Cavalier CFO, Treasurer & Sec.
Mr. R. Donald Elsey MBA Advisor
Ms. Corinne Noyes Sr. VP of Commercial Strategy & Market Devel.
Dr. Harlan W. Waksal M.D. Exec. Chairman
Dr. Carmichael S. Roberts Jr., Ph.D. Co-Founder
Mr. Ray Knox VP of Operations
Dr. Robert Richard Ph.D. Sr. VP of Technical Operations
Ms. Ellen Cavaleri Sr. VP of Investor Relations & Communications
Ms. Vineeta Belanger Ph.D. Sr. VP of Clinical Affairs

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.9628
Price-to-Sales TTM: 53.5353
IPO Date: 2020-05-01
Fiscal Year End: December
Full Time Employees: 59
Back to stocks